GTF2I and cancer: However, recent studies showed that different BRAF fusions, such as GTF2I-BRAF [24], DGKI-BRAF [25], and TMEM106B-BRAF [26], activated the MAPK pathway, thereby regulating tumor growth in multiple cancers.